Selvita profile image

Ryvu Therapeutics

WSE: RVU

PLN774.6m market cap

PLN48.5 last close

Ryvu Therapeutics is an oncology R&D company. The two most advanced assets in clinical development are SEL24, a dual PIM/FLT3 inhibitor out-licensed to Menarini Group, and wholly owned SEL120, a selective CDK8 inhibitor. Ryvu also has a diversified preclinical R&D pipeline.

Investment summary

Selvita has split into two separate companies. Selvita will continue trading as Ryvu Therapeutics, a newly introduced brand, and will fully focus on innovative drug discovery and development. Selvita CRO, drug discovery services, was spun out into a separate listed entity. We believe both businesses have sufficient momentum to sustain the split. Ryvu Therapeutics R&D pipeline is progressing according to plan and two clinical trials with SEL24 and SEL120 could deliver data over 2019–20. The lead product is SEL120, a CDK8 inhibitor, partnered with the Leukemia & Lymphoma Society for AML. SEL120 is being explored in a Phase Ib trial in AML and HR-MDS with the first patient recruited in September 2019. SEL24 is a dual PIM/FLT3 inhibitor in Phase I/II for AML out-licensed to Menarini in March 2017.

Industry outlook

The profiles of SEL24 and SEL120 are potentially unique compared to existing clinical-stage competitors and both candidates may offer efficacy advantages.

Last updated on 18/10/2019
Sector
Healthcare
Share price graph
Balance sheet
Forecast net cash (PLNm) 98.1
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual 32.1 30.8 44.4
Relative* 34.6 40.3 45.9
52-week high/low 49.4gr/27.5gr
*% relative to local index
Key management
Paweł Przewięźlikowski CEO
Bogusław Sieczkowski COO
Tomasz Nocun IR

Content on Ryvu Therapeutics